期刊文献+

Pelvic Exenteration for Recurrent and Persistent Cervical Cancer 被引量:14

Pelvic Exenteration for Recurrent and Persistent Cervical Cancer
原文传递
导出
摘要 Background: Pelvic exenteration (PE) for primary and recurrent cervical cancer has resulted in favorable survival outcomes, but there are controversies about specific prognosis factors, and up to now, there have been no published reports from China. This study aimed to share our experiences of PE, which were performed in a single institution. Methods: Frorn January 2009 to January 2016, 38 patients with recurrent or persistent cervical cancer were included in the study, and they were followed up until January 2017. Epidemiological and clinicopathological characteristics of patients were compared for survival outcornes in univariate and Cox hazard regression analysis. Results: There were thirty-one and seven patients with recurrent and persistent cervical cancer, respectively. The median age of patients was 45 years (range 29 65 years). Total, anterior, and posterior PE consisted of 52.6%, 28.9%, and 18.4% of cases, respectively. Early and late complications occurred in 21 (55.3%) patients and 15 (39.5%) patients, respectively. Two (5.3%) patients died due to complications related to surgeries within 3 months after PE. The median overall survival (OS) and disease-free survival (DFS) were 28.5 months (range 9-96 months) and 23 rnonths (range 4.-96 months), respectively, and 5-year OS and DFS were 48% and 40%, respectively. Cox hazard regression analysis showed that, the margin status of the incision and mesorectal lymph node status were independent risk factors liar OS and DFS. Conclusion: In our patients with rect.rrent and persistent cervical cancer, the practice of PE might achieve favorable survival outcomes. Trial Registration: ClinicalTrials.gov, NCT03291275; https://clinicaltrials.gov/ct2/show/NCT03291275?term-NCT03291275&rank = 1. Background: Pelvic exenteration (PE) for primary and recurrent cervical cancer has resulted in favorable survival outcomes, but there are controversies about specific prognosis factors, and up to now, there have been no published reports from China. This study aimed to share our experiences of PE, which were performed in a single institution. Methods: Frorn January 2009 to January 2016, 38 patients with recurrent or persistent cervical cancer were included in the study, and they were followed up until January 2017. Epidemiological and clinicopathological characteristics of patients were compared for survival outcornes in univariate and Cox hazard regression analysis. Results: There were thirty-one and seven patients with recurrent and persistent cervical cancer, respectively. The median age of patients was 45 years (range 29 65 years). Total, anterior, and posterior PE consisted of 52.6%, 28.9%, and 18.4% of cases, respectively. Early and late complications occurred in 21 (55.3%) patients and 15 (39.5%) patients, respectively. Two (5.3%) patients died due to complications related to surgeries within 3 months after PE. The median overall survival (OS) and disease-free survival (DFS) were 28.5 months (range 9-96 months) and 23 rnonths (range 4.-96 months), respectively, and 5-year OS and DFS were 48% and 40%, respectively. Cox hazard regression analysis showed that, the margin status of the incision and mesorectal lymph node status were independent risk factors liar OS and DFS. Conclusion: In our patients with rect.rrent and persistent cervical cancer, the practice of PE might achieve favorable survival outcomes. Trial Registration: ClinicalTrials.gov, NCT03291275; https://clinicaltrials.gov/ct2/show/NCT03291275?term-NCT03291275&rank = 1.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2018年第13期1541-1548,共8页 中华医学杂志(英文版)
关键词 Cervical Cancer Pelvic Exenteration SURVIVAL Cervical Cancer Pelvic Exenteration Survival
  • 相关文献

参考文献1

二级参考文献23

  • 1Peiretti M, Zapardiel I, Zanagnolo V, et al. Management of recurrent cervical cancer: a review of the literature [J]. Surg Onco1,2012,21 : e59-66.
  • 2Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy[J]. Cancer, 1948,1 : 177-183.
  • 3Berek JS, Howe C, Lagasse LD, et al. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA[J]. Gynecol Oncol,2005,99 : 153-159.
  • 4Wells G, Shea B, O'Connell J, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta- analysis [ EB/OL ] . ( 2013-4-13 ) [ 2013-9-10 ] . http:// www. ohri. ca/programs/elinical_epidemiology/oxfordasp.
  • 5Stanhope CR, Webb MJ, Podratz KC. Pelvic exenteration for recurrent cervical cancer[J] Clin Obstet Gynecol, 1990, 33:897- 909.
  • 6Crozier M, Morris M, Levenback C, et al. adenocarcinoma of the uterine cervix[ J]. Pelvic exenteration for Gynecol Oncol, 199558:74-78.
  • 7Marnitz S, Ktihler C, Miiller M, et al. Indications for primary and secondary exenterations in patients with cervical cancer [ J ]. Gynecol Oneo1,2006,103 : 1023-1030.
  • 8Jurado M, Alc6zar JL, Martinez-Monge R. Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic excnteration: is still the clinical involvement of the pelvis wall a real contraindication? a twenty-year experience [J] Gynecol Oneol,2010,116:38-43.
  • 9Terdn-Poreayo MA, Zeichner-Gancz I, del-Castillo RA, et al. Pelvic exenteration for recurrent or persistent cervical cancer: experience of five years at the National Cancer Institute in Mexico [J]. Med Oncol,2006,23:219-223.
  • 10Yoo HJ, Lim MC, Seo SS, et al. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea[J]. J Gynecol Oncol,2012,23:242-250.

共引文献9

同被引文献50

引证文献14

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部